Evolution of treatment strategies in chronic lymphocytic leukemia. Part 2 of 3-part series: Advances in the treatment of hematologic malignancies

Over the past few decades, the management of chronic lymphocytic leukemia (CLL) has evolved considerably. This advancement is due in part to increasing awareness of the prognostic factors and molecular heterogeneity of the disease, which has helped to identify distinct risk groups for CLL. In addition, novel treatment regimens have demonstrated much higher complete and overall response rates than previously seen with conventional CLL therapy. Indeed, as complete response rates exceed 50%, curative therapy for CLL is within reach. Ongoing clinical research may define the optimal treatment strategies and improve outcomes for patients with CLL.